Drug intelligence / Profile preview

RJV-122

Development stage: Preclinical
Lead developer: Rejenevie Therapeutics
Modality: Cell Therapies

Overview

**RJV-122** is a preclinical Rejenevie Therapeutics immune-restoration program described as a cell-based biologic composed of a proprietary combination of factors isolated from young mobilized peripheral-blood stem and immune cells. The intended mechanism is broad restoration or modulation of immune function rather than engagement of a disclosed single molecular target. Rejenevie has described the program for immune restoration and as part of a broader pipeline intended for oncology and infectious-disease applications. ([rejenevie.com](https://www.rejenevie.com/clinical-program/product-pipeline/))

Beyond the preview

Go deeper on RJV-122.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RJV-122.

Explore the full profile